Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Meda acquires five GlaxoSmithKline OTC products for the US market

This article was originally published in Scrip

Executive Summary

Sweden's Meda acquired two more OTC drugs for the US market from GlaxoSmithKline for SEK180 million ($27 million) at the beginning of January after buying three US OTC products for SEK235 million in December. The acquired products were Vivarin (caffeine), the anti-anaemics Feosol and Palafer (iron salts), the vitamin mixture Geritol and Contac (pseudoephedrine hydrochloride), a treatment for a blocked nose and sinus congestion associated with allergies, colds and flu. Their combined annual sales in the US are worth around SEK180 million.

You may also be interested in...



Poland's new law fixes prices and trade mark-ups of reimbursed drugs

Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.

Global pharma boosts business in Russia - Why Russia (introduction)

In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.

Russia's president Medvedev wants talks on trials mutual recognition with US and EU

Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel